[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574689":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":53,"collaborators":55,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":81,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Applied Biology, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DA-007","ACTIVE_COMPARATOR","Topical DA-007 Solution",[13],"Drug: DA-007",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Topical Placebo Solution",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Topical α1 agonist combination of Phenylephrine + Tyramine + Synephrine",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Topical placebo solution",[15],[30],{"name":31,"affiliation":32,"role":33},"Andy Goren, MD","University of Rome G. Marconi","STUDY_DIRECTOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","16507040850","clinicalstudies@appliedbiology.com",[40],{"facility":41,"status":25,"city":42,"state":25,"zip":25,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University of Rome (\"G. Marconi\")","Rome","Italy","IT",{"type":46,"coordinates":47},"Point",[48,49],12.51133,41.89193,{"lat":49,"lon":48},[52],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[56,58],{"name":57,"class":6},"Daniel Alain, Inc.",{"name":59,"class":6},"Follea International Limited","100574689","phase-3-clinical-study-of-da-007-for-the-treatment-of-chemotherapy-induced-alopecia-100574689",false,"NCT06762548","Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia","Inclusion Criteria:\n\n* Diagnosed with stage I or stage II breast cancer\n* Scheduled but not begun, at least 4 cycles of taxane and\u002For anthracycline-based chemotherapy.\n* Ages 18-65\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Resting blood pressure outside the range of 105-140\u002F 55-99\n* Uncontrolled or severe hypertension\n* Female pattern hair loss or hair loss disorder\n* Folliculitis\n* Scalp psoriasis\n* Seborrheic dermatitis\n* Inflammatory scalp conditions such as lichen planopillaris\n* Subjects wearing wigs prior to chemotherapy\n* Use of MAO inhibitors\n* Unable to provide consent or make allotted clinical visits","FEMALE","18 Years","65 Years",{"count":70,"type":71},140,"ESTIMATED","INTERVENTIONAL",[74],"PHASE3","Clinical Study of DA-007 As a Treatment for Chemotherapy Induced Alopecia",[77,78],"Chemotherapy Induced Alopecia","Chemotherapy Side Effects",[77,80],"Chemotherapy Alopecia","NOT_YET_RECRUITING","2025-05-22",{"date":84,"type":85},"2025-05-23","ACTUAL",{"date":87,"type":71},"2025-10-10",{"date":89,"type":71},"2026-11-06",{"name":5,"class":6},1]